Analysis of the burden of prostate cancer in China in 1990 and 2017

• Published in: Yixue xinzhi zazhi
• Main Authors: Tong DENG, Lin CAI, Zheng CHEN, Jia GUO, Xing HUANG, Chang-Xing KE, Wen-Zhi LI, Li JIANG, Guan-Jun LU, Xiao-Qiang LIU, Jin-Hai FAN, Xian-Tao ZENG
• Format: Article
• Language: Chinese
• Published: Editorial Office of New Medicine 2020-08-01
• Subjects: prostate cancer; incidence; mortality; burden of disease; disability-adjusted life years
• Online Access: https://yxxz.whuznhmedj.com/storage/attach/2008/dXbsVtm3j3eLSt2wdWBYnjK8e7N2uLyxEsJKDPfK.pdf
• ISSN: 1004-5511

Objective To analyze the trend of incidence, mortality and disease burden of prostate cancer in China between 1990 and 2017.Methods Based on the results of the Global Burden of Diseases 2017 (GBD 2017), Incidence, Mortality, Disability-Adjusted Life Years (DALY), Years of Life Lost (YLL), and Years Lived with Disability (YLD) of prostate cancer and its standardized rate were used to describe the burden of prostate cancer in China between 1990 and 2017.Results In 2017, the number of cases of prostate cancer in China was 144,900, the standardized incidence was 16.57 / 100 000, the number of deaths was 51,700, and the standardized mortality was 6.8 / 100 000. Compared with 1990, the number of cases increased by 432.72%, the standardized incidence increased by 98.21%, the number of deaths increased by 158.5%, and the standardized mortality decreased by 3.82%. Incidence and mortality are increasing with age. Compared with 1990, in 2017, the DALY standardization rate of prostate cancer in China decreased by 3.81%, the YLL standardization rate decreased by 9.73%, and the YLD standardization rate increased by 134.56%.Conclusions Compared with 1990, the overall disease burden of prostate cancer in China in 2017 showed a downward trend, but YLD showed an upward trend. The burden of prostate cancer disease in the elderly is still high and should be the focus of attention.